Last mentioned: Mar 24, 2026
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
Agreement Signed
Landmark FTA officially signed, initiating the ratification process.
Regulatory Reversal
FDA agrees to review the application after Moderna addresses concerns.
Refusal to File
FDA issues an RTF citing deficiencies in the initial application.
Rollout Milestone
Acoziborole enters the final stages of regulatory rollout for endemic regions.
Acoziborole Rollout
The first single-dose oral cure begins deployment, enabling 'screen-and-treat' strategies.
BLA Submission
Moderna submits Biologics License Application for mRNA-1010.
Strategic Pivot
Talks resume with a new focus on critical minerals and supply chain security.
Talks Stall
Negotiations collapse in Osaka over agricultural quotas and geographic indications.
Trial Results
Phase 2/3 clinical trial results for Acoziborole show high efficacy.
Negotiations Launched
Formal trade talks begin in Canberra focusing on market access and IP.
Fexinidazole Approval
First all-oral 10-day treatment for sleeping sickness is approved.
Fexinidazole Approval
The first all-oral treatment is approved, requiring 10 days of pills taken with food.
Research Begins
DNDi starts screening compounds for a single-dose HAT treatment.
NECT Launch
Nifurtimox-eflornithine combination therapy improves safety but requires complex intravenous administration.
Melarsoprol Introduced
Arsenic-based treatment becomes standard but carries a 5% mortality rate due to toxicity.
After eight years of complex negotiations, the European Union and Australia have signed a landmark free trade agreement aimed at eliminating regulatory barriers. The deal is set to streamline market access for European biologics while securing critical mineral supply chains essential for advanced medical manufacturing.
The introduction of acoziborole, the first single-dose oral treatment for Human African Trypanosomiasis (sleeping sickness), marks a pivotal shift in global health efforts. Developed through a non-profit partnership between DNDi and Sanofi, the drug offers a simplified path to disease elimination by 2030.
The introduction of Acoziborole, a single-dose oral medication, marks a pivotal shift in the global fight against Human African Trypanosomiasis. This breakthrough treatment simplifies complex therapeutic regimens, potentially enabling the total elimination of the disease by 2030.
Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies.
Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms.
The CDC has issued urgent travel advisories for several popular tourist destinations following a confirmed spread of poliovirus. This development signals a significant setback for global eradication efforts and is expected to drive a surge in demand for inactivated poliovirus vaccines (IPV).
The CDC has issued a series of travel notices for popular international tourist destinations following a spike in polio detections. The move signals a shift in global health security, requiring travelers to verify immunization status and potentially seek adult boosters before departure.
The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.